Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is a leading biotechnology company known for its innovative approach to drug development. Established in 1988, the company is headquartered in Tarrytown, New York with over 7,000 employees worldwide. Regeneron is dedicated to transforming patients' lives through science and its mission is to consistently deliver new medicines with significant therapeutic benefits.
The company's portfolio includes seven FDA-approved medications – Praluent (cholesterol treatment), Kevzara (rheumatoid arthritis treatment), Libtayo (cutaneous squamous cell carcinoma treatment), Eylea (macular degeneration treatment), Dupixent (eczema, asthma, and nasal polyps treatment), Zaltrap (colorectal cancer treatment) and Arcalyst (autoinflammatory conditions treatment). Meanwhile, Regeneron’s research and development team is continually working on developing innovative new treatments for a wide range of diseases.
Regeneron is perhaps best known for its genetics-driven approach to drug discovery and development. Its technologies and capabilities include VelociGene, used for validating potential drug targets; VelociMouse; used for shortening the timeframe for drug testing and VelocImmune, a tool which helps develop fully human monoclonal antibodies.
Given the ongoing COVID-19 pandemic, it's important to note that Regeneron's antiviral cocktail, REGEN-COV (Casirivimab with Imdevimab), has been authorized under an emergency use authorization by the FDA for the treatment and prevention of COVID-19.
Regeneron has been recognized repeatedly for its commitment to innovation and excellence. It was named to Forbes' World's Most Innovative Companies List and Fortune's World's Most Admired Companies List. Notably, in 2020, Science Magazine named Regeneron as the top employer in the global biopharmaceutical industry for the third year in a row.
Regeneron's co-founder, President and Chief Scientific Officer, Dr. George Yancopoulos, holds more than 100 patents and is the highest number patent-holder among New York State's biotechnology professionals. Meanwhile, other leaders of the company have been recognized for their contributions to healthcare, including CEO Leonard Schleifer, who was named EY’s Entrepreneur of the Year in 2019.
In conclusion, Regeneron Pharmaceuticals is a leader in biotechnology industry known for its genetics-driven approach and is committed to harnessing the power of science to bring new hope and therapies to patients across the world.